<- Go Home
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Market Cap
$45.0B
Volume
4.8M
Cash and Equivalents
$3.1B
EBITDA
$1.7B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$4.4B
Profit Margin
79.50%
52 Week High
$95.25
52 Week Low
$58.93
Dividend
N/A
Price / Book Value
4.44
Price / Earnings
31.71
Price / Tangible Book Value
6.27
Enterprise Value
$41.9B
Enterprise Value / EBITDA
24.43
Operating Income
$1.5B
Return on Equity
16.51%
Return on Assets
8.42
Cash and Short Term Investments
$3.9B
Debt
$699.4M
Equity
$10.2B
Revenue
$5.5B
Unlevered FCF
$1.5B
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium